Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPCASTRO, Tazia Lopes deCAMBIAIS, Amanda Magalhaes Vilas BoasSFORSIN, Andrea Cassia PereiraPINTO, Vanusa BarbosaFALCAO, Maria Alice Pimentel2024-02-152024-02-152023EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, v.11, article ID 100289, 5p, 2023https://observatorio.fm.usp.br/handle/OPI/58258Background: The consumption of antimicrobials and the growing resistance of infectious agents to these drugs are not related only to health issues, but also to economic parameters.Objectives: The study objective was to evaluate the consumption of antimicrobials in General and Covid-19 Intensive Care Units (ICUs) and the impact on institutional costs in the largest institute of a tertiary public hospital.Methods: This is a quantitative and retrospective study, which analyzed consumption, through the Defined Daily Dose (DDD), and the annual direct cost of antimicrobials in Reais (R$) and Dollars (US$), from January to December 2021. Results: The total annual consumption (DDD/1000 patient-day) of antimicrobials in the ICUs was 14,368.85. beta-Lactams had the highest total annual value, with a DDD/1000 patient-day of 7062.98, being meropenem the antimi-crobial that reached the highest consumption (3107.20), followed by vancomycin (2322.6). Total consumption was higher in Covid-19 ICUs than in General ICUs, and the annual direct cost of antimicrobials in ICUs was US$560,680.79.Conclusions: The study showed high consumption of broad-spectrum antimicrobials, highlighting the importance of structuring programs to manage the use of antimicrobials, both to reduce antimicrobial consumption and hospital costs, consolidating rational use even in pandemic scenarios.engopenAccessAnti-infective agentsCost analysisCritical carefungal-infectionsrational useantibioticscovid-19outcomesimpactarticleCopyright ELSEVIER10.1016/j.rcsop.2023.100289Pharmacology & Pharmacy2667-2766